Lupus

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kashipaz, M R A.
Right arrow Articles by Todd, I
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kashipaz, M R A.
Right arrow Articles by Todd, I
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Lupus, Vol. 12, No. 5, 356-363 (2003)
DOI: 10.1191/0961203303lu338oa

Assessment of Be1 and Be2 cells in systemic lupus erythematosus indicates elevated interleukin-10 producing CD5+ B cells

M R Amel Kashipaz

Division of Molecular and Clinical Immunology, School of Clinical Laboratory Sciences, University of Nottingham, Queen’s Medical Centre, Nottingham, UK

M L Huggins

Division of Molecular and Clinical Immunology, School of Clinical Laboratory Sciences, University of Nottingham, Queen’s Medical Centre, Nottingham, UK

P Lanyon

Division of Molecular and Clinical Immunology, School of Clinical Laboratory Sciences, University of Nottingham, Queen’s Medical Centre, Nottingham, UK

A Robins

Division of Molecular and Clinical Immunology, School of Clinical Laboratory Sciences, University of Nottingham, Queen’s Medical Centre, Nottingham, UK

R J Powell

Division of Molecular and Clinical Immunology, School of Clinical Laboratory Sciences, University of Nottingham, Queen’s Medical Centre, Nottingham, UK

I Todd

Division of Molecular and Clinical Immunology, School of Clinical Laboratory Sciences, University of Nottingham, Queen’s Medical Centre, Nottingham, UK, ian.todd{at}nottingham.ac.uk

Recent studies indicate that normal B cells can be primed to differentiate into two distinct cytokine- secreting effector subsets, Be1 and Be2. The aim of this study was to analyse, for the first time, Be1 and Be2 cells at the single cell level in SLE patients using the recently developed technique of flow cytometry for intracellular cytokines. Peripheral blood mononuclear cells (PBMC) from SLE patients and age- and sex-matched normal controls were cultured for 24 h in the presence or absence of phorbal myristate acetate and ionomycin (PMA=I) or lipopolysaccharide (LPS). The production of type 1 (IFN-g, IL-2) and type 2 (IL-4, IL-5, IL-6, IL-10, IL-13) cytokines by B cells (and IL-10 production by fractionated CD5+ and CD57 B cells) was investigated using an intracellular cytokine staining technique and flow cytometry. In the absence of PMA=I stimulation, the percentage of B cells from SLE patients was significantly lower than those of normal subjects and significantly more SLE B cells spontaneously produced IL-10 than controls. Moreover, CD5+ B cells from SLE patients were enriched for cells with signs of previous in vivo activation and for high levels of IL-10 production. A significant positive correlation was observed between the percentage of IL-10- and IL-6-producing PMA=I-stimulated B cells in SLE patients, but not in controls. There were no significant differences in the production of other cytokines by B cells of SLE patients and normal subjects. In conclusion, a general alteration of type 1 and type 2 cytokine production by B cells is not observed in SLE patients. The role of B cell cytokines in the pathogenesis of SLE appears to be exerted by elevated secretion of in vivo IL-10, which may play an important role in the immune dysregulation observed in SLE patients. Moreover, the cross regulation of IL-10 and IL-6 is disrupted in SLE patients.

Key Words: Be1 cells • Be2 cells • CD5+ B cells • cytokines • systemic lupus erythematosus


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
H. Sekine, H. Watanabe, and G. S. Gilkeson
Enrichment of Anti-Glomerular Antigen Antibody-Producing Cells in the Kidneys of MRL/MpJ-Faslpr Mice
J. Immunol., March 15, 2004; 172(6): 3913 - 3921.
[Abstract] [Full Text] [PDF]